Clinical trials
Cancer Risk clinical trials
Below are recruiting cancer risk clinical trials, each written for real people, not researchers. We’re tracking 717 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06204315RecruitingPhase 2
Spine radiosurgery for spinal cord compression
This trial tests a precise radiation technique for people whose spinal tumors are very close to the spinal cord or nerves. It aims to safely give higher radiation doses while limiting damage to the cord.
Houston, TexasAges 18 years+ - NCT06282016Recruiting
Risk factors for neuroendocrine tumors in Bavaria
This study looks at medical records from people in Bavaria to find out what might increase the risk of developing neuroendocrine neoplasms (a rare type of tumor). By reviewing routine health data, researchers hope to discover early signs or risk factors that could help with future detection and care.
Nuremberg, BavariaAges Any age - NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT04708054RecruitingPhase 2/Phase 3
Venetoclax with busulfan chemo for high-risk AML or MDS
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
Houston, TexasAges 18–70 - NCT05010122RecruitingPhase 1/Phase 2
Testing venetoclax and gilteritinib with ASTX727 for FLT3 leukemia
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
Houston, TexasAges 18 years+ - NCT06807606RecruitingPhase 2
Cord blood transplant after relapse from first transplant
This trial tests a second transplant using two donated umbilical cord blood units for people whose blood cancer returned after a first stem cell transplant. It aims to offer a potential cure for high-risk blood cancers.
Houston, TexasAges Up to 60 years - NCT06930521Recruiting
Monitoring heart health during HER2 therapy for breast cancer
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
Toronto, OntarioAges 18–79 - NCT00870129Recruiting
MRI mapping to plan radiation for certain brain tumors
This study uses MRI scans to find higher-risk areas in certain brain and other solid tumors and help plan radiation treatment. It also looks for changes in tumor “metabolites” (chemicals in the tumor) that may relate to how the tumor behaves.
New York, New YorkAges 18 years+ - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Birmingham, AlabamaAges 18–59 - NCT06872333RecruitingPhase 2
Stem cell transplant from a matched sibling for blood disorders
This trial tests whether a stem cell transplant from a fully matched sibling donor can help people with serious blood disorders like sickle cell disease or thalassemia. It aims to replace the faulty blood system with a healthy one from the donor.
Minneapolis, MinnesotaAges Up to 55 years - NCT01624805RecruitingPhase 2
Immunosuppressant treatment to help low blood counts in some bone marrow disorders
This trial tests a group of immune-suppressing medicines (with steroids and growth-factor injections) for people with aplastic anemia or certain low-risk myelodysplastic syndromes. The goal is to improve bone marrow function and reduce problems caused by low blood counts, such as fatigue, infections, or bleeding.
Houston, TexasAges 18 years+ - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Berkeley, CaliforniaAges 18 years+ - NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Basking Ridge, New JerseyAges 18 years+ - NCT07363980Enrolling by invitation
Heart CT Study for Rheumatoid Arthritis Patients
This study uses a special heart CT scan to look for early signs of heart disease in people with rheumatoid arthritis. It may help find problems before symptoms start.
AarhusAges 50–75 - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT05705687Recruiting
Testing a treatment plan for higher-risk testicular cancer
This trial checks whether a specific treatment approach works better for men with higher-risk non-seminomatous germ-cell tumors that have spread. Doctors will use tumor marker changes and where the cancer started (often the chest area) to help guide treatment choices.
VillejuifAges 16 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT05918510Recruiting
Blood and tumor study for virus markers in throat cancer
This study looks at virus-related markers and tiny gene regulators (microRNAs) in tumor tissue from people with certain throat cancers caused by human papilloma virus (HPV). It’s observational, meaning it does not change your treatment, but results may help doctors better understand these cancers and how they behave.
RomeAges 18 years+ - NCT06104592RecruitingPhase 2
Radiation before CAR T-cell therapy for high-risk large B-cell lymphoma
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Tampa, FloridaAges 18 years+ - NCT06013618RecruitingPhase 2
Naxitamab for high-risk or relapsed neuroblastoma in children
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
Guangzhou, GuangdongAges 1 year+ - NCT04239157RecruitingPhase 2
Canakinumab shot for lower-risk MDS and related blood disorders
This trial tests canakinumab, a medication that blocks inflammation, given as a skin (subcutaneous) injection. It is for adults with lower-risk myelodysplastic syndromes (MDS) or a related condition (chronic myelomonocytic leukemia or CCUS) to see if it can improve blood counts and reduce problems like anemia or transfusion needs.
Houston, TexasAges 18 years+ - NCT04493164RecruitingPhase 2
CPX-351 plus ivosidenib for IDH1-mutated leukemia or high-risk MDS
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Houston, TexasAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT04140487RecruitingPhase 1/Phase 2
Study drugs for certain FLT3-mutated blood cancers that have returned
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
Houston, TexasAges 18 years+
Hear when a new Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer risk?
- Yes. Clin2 currently lists 717 recruiting cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.